# EDGAR Filing Document

**Accession Number:** 0002126287
**File Stem:** 0002126287-26-000001
**Filing Date:** 2026-4
**Character Count:** 6404
**Document Hash:** ce870cf1ab2ecd436bf8cc7b750e6408
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002126287-26-000001.hdr.sgml**: 20260413

**ACCESSION NUMBER**: 0002126287-26-000001

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260413

**DATE AS OF CHANGE**: 20260413

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Barinthus Biotherapeutics plc.
- **CENTRAL INDEX KEY:** 0001828185
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93002
- **FILM NUMBER:** 26857663

**BUSINESS ADDRESS:**
- **STREET 1:** 20400 CENTURY BLVD
- **STREET 2:** SUITE 210
- **CITY:** GERMANTOWN
- **STATE:** MD
- **ZIP:** 20874
- **BUSINESS PHONE:** 44 (0) 1865 818808

**MAIL ADDRESS:**
- **STREET 1:** 20400 CENTURY BLVD
- **STREET 2:** SUITE 210
- **CITY:** GERMANTOWN
- **STATE:** MD
- **ZIP:** 20874

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vaccitech plc
- **DATE OF NAME CHANGE:** 20210407

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vaccitech Ltd
- **DATE OF NAME CHANGE:** 20201014
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** International Generosity Foundation Trust
- **CENTRAL INDEX KEY:** 0002126287

**ORGANIZATION NAME:**
- **EIN:** 843754469
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 1901 ULMERTON ROAD
- **STREET 2:** SUITE 400
- **CITY:** CLEARWATER
- **STATE:** FL
- **ZIP:** 33762
- **BUSINESS PHONE:** 7275026022

**MAIL ADDRESS:**
- **STREET 1:** 1901 ULMERTON ROAD
- **STREET 2:** SUITE 400
- **CITY:** CLEARWATER
- **STATE:** FL
- **ZIP:** 33762

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Barinthus Biotherapeutics plc.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Robert Giffen Collins**<br>1901 Ulmerton Road, Suite 400<br>Clearwater FL 33762<br>8138178035

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**02/03/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**International Generosity Foundation Trust** | Name of reporting person<br>**International Generosity Foundation Trust** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**FLORIDA** | Citizenship or place of organization<br>**FLORIDA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2734189.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2734189.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2734189.00** | Aggregate amount beneficially owned by each reporting person<br>**2734189.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.7%** | Percent of class represented by amount in Row (11)<br>**6.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
Barinthus Biotherapeutics plc.

**(c) Address of Issuer's Principal Executive Offices:**
20400 CENTURY BLVD, SUITE 210, GERMANTOWN, MD, 20874

**Item 4. Purpose of Transaction**

The Reporting Person acquired the securities for investment purposes and in connection with its charitable activities.

The Reporting Person may, from time to time, sell or otherwise dispose of some or all of the securities, including to support its charitable purposes, or acquire additional securities, depending on market conditions and other factors.

Except as set forth above, the Reporting Person has no present plans or proposals that relate to or would result in any of the actions described in Items 4(a) through (j) of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Aggregate Number of Shares Owned: 2,734,189
Percentage of Class of Securities Identified: 6.7

**(b)**
The Reporting Person has sole voting power with respect to 2,734,189 shares, shared voting power with respect to 0 shares, sole dispositive power with respect to 2,734,189 shares, and shared dispositive power with respect to 0 shares.

**(c)**
The Reporting Person has not effected any transactions in the securities of the Issuer during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The Reporting Person does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with respect to any securities of the Issuer, other than as described in this Schedule 13D.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** International Generosity Foundation Trust

**Signature:** Robert Giffen Collins

**Name/Title:** Robert Giffen Collins

**Date:** 04/13/2026